Acepodia

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia, a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). Combining ExpertiseThe…